Fig 1.
Four biomarker sub-studies of clinical trials were pooled for clustering before further analysis of each cluster.
A random selection of patients from the RA clinical trials were selected for biomarker analysis. Patients with missing data from the panel of biomarkers analysed were removed from the study when included in the arthritic cohort.
Table 1.
Baseline patient demographics for four cohorts used in this study, LITHE, OSKIRA, SMC1 and SMC2.
All measurements were taken at the start of each of the clinical trials prior to treatment.
Fig 2.
1233 patients from 4 clinical trials; two rheumatoid arthritis (RA) and two osteoarthritis (OA), were clusters based on 7 tissue specific blood based biomarkers measuring bone resorption and formation, cartilage degradation, macrophage activity, interstitial matrix degradation and CRP metabolites.
5 clusters were found with two high inflammatory RA endotypes and one low inflammatory RA endotype, and a final “mixed” endotype. OA patients were clearly separated from RA patients as expected.
Table 2.
Descriptive statistics for each cluster identified through hierarchical clustering, with p-values calculated using ANOVA test to identify differences between the clusters.
Table 3.
Mean and standard deviation of clinical variables for placebo patients in each cluster identified, where p-values have been measured using ANOVA test or Chi squared.